Vandetanib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AOTMIT (Poland), G-BA (Germany) and HAS (France), among others, recommended or restricted vandetanib, while AWMSG (Wales) and NICE (England) did not recommend it.
Assessment has run over 9.8 years, from 11 Jun 2012 at SMC (Scotland) to 18 Mar 2022 at G-BA (Germany).
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for vandetanib, 1 submission was never made — an outcome set by the company rather than the assessor.
4 distinct indication wordings are recorded for vandetanib by the agencies that label one in English (AWMSG, NICE and SMC).
SMC (Scotland) was first to assess vandetanib, on 11 Jun 2012; NICE (England) did not open a file until 12 Dec 2018 — a wide spread of 6.5 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
3 of the 7 agencies here assessed vandetanib more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for vandetanib.
The full ledger for vandetanib reads 3 recommended, 2 not recommended, 2 other and 1 no benefit, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 18 Mar 2022 | Caprelsa — benefit assessment §35a | added benefit: not proven | source |
| HAS (France) | 20 Feb 2019 | Listing renewal (Transparency Committee) | SMR substantial | source |
| NICE (England) | 12 Dec 2018 | NICE TA550 | not recommended | source |
| AOTMIT (Poland) | 1 Oct 2018 | programu lekowego „Leczenie agresywnego i objawowego, nieoperacyjnego, miejscowo zaawansowanego lub przerzutowego raka r… | recommended | source |
| AWMSG (Wales) | 25 Sep 2014 | Treatment of aggressive and symptomatic medullary thyroid cancer in patients with unresectable locally advanced or metas… | superseded (full) | source |
6 further decisions for vandetanib, across 5 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 11 decisions for vandetanib from 7 agencies, 2012 to 2022. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.